News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Nektar Therapeutics Ovarian Cancer Drug Benefits Women in Study
June 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- About 48 percent of women with advanced ovarian cancer saw sustained benefits from treatment with Nektar Therapeutics' experimental drug NKTR-102 in a mid-stage study, the company said on Sunday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Phase 3
MORE ON THIS TOPIC
Huntington’s disease
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
July 13, 2026
·
4 min read
·
Heather McKenzie
Insights
From sequence to scale: Gene editing’s new era in biologics manufacturing
July 10, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Antibody-drug conjugates
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
July 10, 2026
·
1 min read
·
Gabrielle Masson
Cardiovascular disease
AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space
July 10, 2026
·
3 min read
·
Tristan Manalac
